Claims for Patent: 7,741,345

Summary for Patent: 7,741,345

Title:	AZA-peptide protease inhibitors
Abstract:	The invention is related to compounds of Formula I: ##STR00001## or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
Inventor(s):	Cannizzaro; Carina E. (Foster City, CA), Chen; James M. (San Ramon, CA), Desai; Manoj C. (Pleasant Hill, CA), Mitchell; Michael L. (Hayward, CA), Swaminathan; Sundaramoorthi (Burlingame, CA), Xu; Lianhong (Palo Alto, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	11/880,067
Patent Claims:	1. A compound of formula (I), ##STR00615## wherein, X.sup.1 and X.sup.2 are each independently --C(O)--; Y is --O--; L.sup.1 is --O--, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene, or substituted alkynylene; L.sup.2 is a covalent bond or --NR.sup.8--; with the proviso that when L.sup.1 is alkylene and L.sup.2 is a covalent bond, R.sup.1 is not a substituted heterocyclyl selected from the group of heterocyclyls consisting of: ##STR00616## wherein U and V are independently O, S, or NH; n is 1 or 2; L.sup.3 and L.sup.5 are each independently a covalent bond, alkylene or substituted alkylene; L.sup.4 and L.sup.6 are each independently a bond, or --O--; Ar.sup.1 and Ar.sup.3 are each independently aryl or substituted aryl; Ar.sup.2 is heterocyclyl or sybstituted heterocyclyl; R.sup.1 is cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, or --C(O)OR.sup.9; R.sup.2, R.sup.4 and R.sup.5 are H; R.sup.3 is --OH; R.sup.6 and R.sup.6a are each independently H, halo, cyano, alkyl, substituted alkyl, haloalkyl, substituted haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R.sup.8 is H, alkyl, or substituted alkyl; R.sup.9 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, or substituted alkynyl; m is 0 or 1; n is 0, 1 or 2; or a pharmaceutically acceptable salt, and/or ester thereof. 2. The compound of claim 1, wherein each L.sup.3 and L.sup.5 is independently methylene, ethylene, or propylene. 3. The compound of claim 1, wherein Ar.sup.1 and Ar.sup.3 are phenyl or naphthyl. 4. The compound of claim 1, wherein -L.sup.5-Ar.sup.3 is ##STR00617## wherein, L.sup.6 is a covalent bond, or --O--; R.sup.6 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoxy, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; m is 0, or 1. 5. The compound of claim 4, wherein R.sup.6 is phenyl or pyridine. 6. The compound of claim 4, wherein L.sup.6 is --O--; R.sup.6 is alkyl or substituted alkyl. 7. The compound of claim 1, wherein L.sup.3 is alkylene; Ar.sup.1 is aryl or substituted aryl. 8. The compound of claim 5, wherein R.sup.6a is ##STR00618## wherein A.sup.1 is O, S, S(O), or S(O).sub.2; R.sup.12 is H, alkyl, substituted haloalkyl, substituted haloalkyl, hydroxyalkyl, substituted hydroxyalkyl, alkoxyalkyl or substituted alkoxyalkyl; p is 1 or 2; and q is 0, 1, 2, or 3. 9. The compound of 1, wherein Ar.sup.2 is bicyclic-heterocyclyl having from 1 to 3 heteroatoms selected from O, S, and N. 10. The compound of claim 9, wherein Ar.sup.2 is ##STR00619## wherein, A.sup.2 and A.sup.3 are each independently O or S; R.sup.13 and R.sup.14 are each independently H, alkyl, substituted haloalkyl, substituted haloalkyl, hydroxyalkyl, substituted hydroxyalkyl, alkoxyalkyl or substituted alkoxyalkyl; t is 1, 2, or 3; v is 1, 2, 3, or 4; and w is 1 or 2. 11. The compound of claim 1, wherein L.sup.1 is substituted alkylene, L.sup.2 is N(R.sup.8) wherein R.sup.8 is H or alkyl; R.sup.1 is --C(O)OR.sup.9 wherein R.sup.9 is alkyl. 12. The compound of claim 11, wherein R.sup.1-L.sup.2-L.sup.1- is ##STR00620## wherein R.sup.9 is alkyl; R.sup.8, R.sup.17, and R.sup.18 are independently H, alkyl, or substituted alkyl. 13. The compound of claim 1, wherein, X.sup.1 is --C(O)--; X.sup.2 is --C(O)--; Y is --O--; L.sup.1 is --O--; L.sup.2 is a covalent bond; L.sup.3 and L.sup.5 are each independently alkylene; L.sup.4 is a covalent bond; Ar.sup.1 and Ar.sup.3 are each independently aryl, substituted aryl; R.sup.6a is heteroaryl or substituted heteroaryl; Ar.sup.2 is heterocyclyl or substituted heterocyclyl; R.sup.1 is heterocyclyl or substituted heterocyclyl; R.sup.3 is --OH or --O-PG wherein PG is a protecting group; m is 0; and n is 1. 14. The compound of claim 1, wherein, X.sup.1 is --C(O)--; X.sup.2 is --C(O)--; Y is --O--; L is alkylene; L.sup.2 is N(R.sup.8); L.sup.3 and L.sup.5 are each independently alkylene; L.sup.4 is a covalent bond; L.sup.6 is a bond or --O--; Ar.sup.1 and Ar.sup.3 are each independently aryl, substituted aryl; R.sup.6 is alkyl or substituted alkyl; R.sup.6a is heteroaryl or substituted heteroaryl; Ar.sup.2 is heterocyclyl or substituted heterocyclyl; R.sup.1 is CO(O)R.sup.9; R.sup.2, R.sup.4 and R.sup.5 are H; R.sup.3 is --OH; R.sup.8 is H; R.sup.9 is methyl; m is 1; n is 1. 15. The compound of claim 1, selected from the group consisting of ##STR00621## ##STR00622## ##STR00623## ##STR00624## ##STR00625## ##STR00626## ##STR00627## ##STR00628## ##STR00629## ##STR00630## ##STR00631## ##STR00632## or a pharmaceutically acceptable salt, solvate and/or ester thereof. 16. A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, colvate, and/or ester thereof, and a pharmaceutically acceptable carrier or exipient. 17. The pharmaceutical composition of claim 16, further comprising: at least one additional active agent, wherein said at least one additional active agent is selected from the group consisting of: HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, entry inhibitors, gp120 inhibitors, G6PD and NADH-oxidase inhibitors, CCR5 inhibitors, other drugs for treating HIV, and mixtures thereof. 18. The pharmaceutical composition of claim 17, wherein: (1) said HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopiriavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, 800334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35, and AG 1859; (2) said HIV non-nucleoside inhibitors of reverse transcriptase are selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773, UK-453061, and RDEA806; (3) said HIV nucleoside inhibitors of reverse transcriptase are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (.+-.-FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), GS-7340, amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003); (4) said HIV nucleotide inhibitors of reverse transcriptase are selected from the group consisting of tenofovir and adefovir; (5) said HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), elvitegravir, L-870812, and L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK-2048, and BA 011; (6) said gp41 inhibitor are selected from the group consisting of enfuvirtide, sifuvirtide, FB006M, and TRI-1144; (7) said CXCR4 inhibitor is AMD-070; (8) said entry inhibitor is SP01A; (9) said gp120 inhibitor is BMS-488043 or BlockAide/ CR; (10) said G6PD and NADH-oxidase inhibitor is immunitin; (11) said CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5 mAb004; and (12) said other drugs for treating HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS119, ALG 889, and PA-1050040 (PA-040). 19. The compound of claim 1 having structure of formula Ia: ##STR00633## wherein L.sup.4 is independently a bond or --O--; L.sup.6 is a bond; R.sup.6 is heteroaryl; R.sup.6a is independently hydrogen, halo, cyano, alkyl or haloalkyl. 20. The compound of claim 19, wherein R.sup.6 is pyridine. 21. The compound of claim 19, wherein L.sup.4 is independently a bond or --O--; L.sup.6 is a bond; R.sup.6 is pyridine; R.sup.6a is independently hydrogen, halo, cyano, (C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)haloalkyl.

Details for Patent 7,741,345

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2026-07-21